Lancet Neurology

Article	Citations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	3107
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series	992
Challenges in the diagnosis of Parkinson's disease	672
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches	485
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	482
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	448
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria	424
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	374
Traumatic brain injury: progress and challenges in prevention, clinical care, and research	344
Myelin-oligodendrocyte glycoprotein antibody-associated disease	319
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias	298
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study	294
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	281
New insights into atypical Alzheimer's disease in the era of biomarkers	277
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study	269
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	256
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	244
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study	237
Neuroimaging standards for research into small vessel disease—advances since 2013	222
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data	209
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study	206
Multiple sclerosis progression: time for a new mechanism-driven framework	203
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials	192
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis	184
The neuropsychiatry of Parkinson's disease: advances and challenges	182

Progress towards therapies for disease modification in Parkinson's disease	180
Functional neurological disorder: new subtypes and shared mechanisms	176
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	175
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation	173
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease	169
Moyamoya disease: diagnosis and interventions	148
Monogenic variants in dystonia: an exome-wide sequencing study	147
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study	145
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	142
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	141
Neuromodulation in epilepsy: state-of-the-art approved therapies	139
PET imaging of neuroinflammation in neurological disorders	139
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder	138
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial	137
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial	134
Post-viral effects of COVID-19 in the olfactory system and their implications	133
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment	128
Alzheimer's disease associated with Down syndrome: a genetic form of dementia	127
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study	127
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	125
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis	124
A biological classification of Huntington's disease: the Integrated Staging System	124
Diagnosis and classification of optic neuritis	118
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials	117
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial	117
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances	117
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial	115
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials	115
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial	113
Forecasting seizure risk in adults with focal epilepsy: a development and validation study	109
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled,	106
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	105
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study	105
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial	105
Mitochondrial disease in adults: recent advances and future promise	105
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches	103
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy	102
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	101
New therapies for neuromyelitis optica spectrum disorder	101
Epilepsy in China: major progress in the past two decades	100
Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments	99
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders	98
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	96
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria	95
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study	95
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	92
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	90
Thrombolysis for acute ischaemic stroke: current status and future perspectives	88
Amantadine in the treatment of Parkinson's disease and other movement disorders	88
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission	87

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial	86
Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial	84
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment	84
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)	82
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	81
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	81
Ageing and multiple sclerosis	81
Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohor	79
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	79
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial	77
Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial	75
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions	73
Menstrual migraine: a distinct disorder needing greater recognition	73
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study	73
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study	73
Sleep function: an evolutionary perspective	70
Sleep disorders in autoimmune encephalitis	70
Spontaneous intracranial hypotension: searching for the CSF leak	70
Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care	70
Diagnosis and treatment of orthostatic hypotension	68
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment	67
Cognitive-motor dissociation and time to functional recovery in patients with acute brain injury in the USA: a prospective observational cohort study	65
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	65
CDKL5 deficiency disorder: clinical features, diagnosis, and management	65
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, pha	65
Management of atherosclerotic extracranial carotid artery stenosis	64
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study	63
The role of manganese dysregulation in neurological disease: emerging evidence	63
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	62
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	61
Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study	59
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial	58
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase	58
Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study	58
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, pl	57
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	57
Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours	57
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study	56
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	56
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial	55
Sleep apnoea and ischaemic stroke: current knowledge and future directions	55
Progression of cerebral amyloid angiopathy: a pathophysiological framework	55
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme	54
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 tr	54
Intracerebral haemorrhage expansion: definitions, predictors, and prevention	54
Long COVID: understanding the neurological effects	53
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	53
Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial	53
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study	52
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	52
Intraoperative electrocorticography using high-frequency oscillations or spikes to tailor epilepsy surgery in the Netherlands (the HFO trial): a randomised, single-blind, adaptive non-inferiority tria	52
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	52
Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial	52
Antipsychotic prescribing to people with dementia during COVID-19	52
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial	51
Tuberculous meningitis: progress and remaining questions	50
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies	49
Traumatic brain injury as a chronic disease: insights from the United States Traumatic Brain Injury Model Systems Research Program	49
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial	49
Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders	48
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial	48
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy	48
Emerging therapies for Duchenne muscular dystrophy	47
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial	47
Drug resistance in epilepsy	46
Personalised virtual brain models in epilepsy	45
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial	45
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy	45
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial	45
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	44
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	42
Parkinson's disease outside the brain: targeting the autonomic nervous system	42
Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack:	42
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	40
Research priorities to improve stroke outcomes	40
Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study	40
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study	40
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach	40
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	39
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	39

Genetics of multiple sclerosis: lessons from polygenicity	39
Tourette syndrome: clinical features, pathophysiology, and treatment	39
Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease	38
Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management	38
Sleep research in 2020: COVID-19-related sleep disorders	38
Family planning considerations in people with multiple sclerosis	37
Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	37
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crosso	37
Imaging of the optic nerve: technological advances and future prospects	36
Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China	36
BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study	35
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	34
The role of diet in secondary stroke prevention	34
Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke	34
Lifestyle factors and migraine	34
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	34
Anti-CD19 CAR T cells for refractory myasthenia gravis	33
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial	32
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial	32
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study	31
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study	31
Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	31
Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group,	31
Heart health meets cognitive health: evidence on the role of blood pressure	30
Advances in Alzheimer's disease research over the past two decades	30
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	29
Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial	28
Guillain-Barré syndrome after vaccination against COVID-19	28
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	27
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	27
Autosomal dominant cerebellar ataxias: new genes and progress towards treatments	26
Carpal tunnel syndrome: updated evidence and new questions	25
The Neurological Pupil index for outcome prognostication in people with acute brain injury (ORANGE): a prospective, observational, multicentre cohort study	24
Chronic effects of inflammation on tauopathies	24
Palliative care to support the needs of adults with neurological disease	23
Towards a new classification of atrial fibrillation detected after a stroke or a transient ischaemic attack	23
Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice	23
Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial	23
A new definition of brain health	23
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial	23
Multiple sclerosis under the spotlight	21
Multiple sclerosis: two decades of progress	21
Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial	21
Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial	21
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial	21
The necessity of diplomacy in brain health	21
Prediction of autism in infants: progress and challenges	21
The assessment of dysphagia after stroke: state of the art and future directions	20
The relevance of social and commercial determinants for neurological health	20
Brain network reorganisation in an adolescent after bilateral perinatal strokes	20
Freezing of gait before the introduction of levodopa	20
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	20
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial	20
Traumatic brain injury over the past 20 years: research and clinical progress	20
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial	19
Lecanemab slows Alzheimer's disease: hope and challenges	19
Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study	19
WHO launches its Global Action Plan for brain health	19
BTK inhibitors as potential therapies for multiple sclerosis	18
New hope for advancing neuropalliative care	18
Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study	18
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study	18
Off-label use of aducanumab for cerebral amyloid angiopathy	17
Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke: an international, prospective cohort study	17
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial	17
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses	17
Parkinson's disease needs an urgent public health response	17
MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19	16
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial	16
The mechanisms of smell loss after SARS-CoV-2 infection	16
Approach and management to patients with neurological disorders reporting sexual dysfunction	16
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial	16
Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort study	16
Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study	16
Towards functional improvement of motor disorders associated with cerebral palsy	16
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes	15
The Mobile Toolbox for monitoring cognitive function	15
The International Parkinson Disease Genomics Consortium Africa	15
Movement disorders research in 2021: cracking the paradigm	15
Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 t	15
Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial	14
Preparing for disease-modifying therapies in Alzheimer's disease	14
Could SARS-CoV-2 cause tauopathy?	14
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	14
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders	14
The complex pathway between amyloid β and cognition: implications for therapy	14
Diabetes and Alzheimer's disease: shared genetic susceptibility?	14
Parkinson's disease in traditional Chinese medicine	13
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial	13
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab	13
Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis	13
Surgical decompression in acute spinal cord injury: earlier is better	13
Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial	13
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	13
Biomarkers for dementia: too soon for routine clinical use	12